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Abstract: An estimation of myocardial mechano-energetic efficiency (MEE) per unit of left ventricular
(LV) mass (MEEi) can significantly predict composite cardiovascular (CV) events in treated
hypertensive patients with normal ejection fraction (EF), after adjustment for LV hypertrophy
(LVH). We have tested whether MEEi predicts incident heart failure (HF), after adjustment for LVH,
in the population-based cohort of a “Strong Heart Study” (SHS) with normal EF. We included 1912
SHS participants (age 59 ± 8 years; 64% women) with preserved EF (≥50%) and without prevalent
CV disease. MEE was estimated as the ratio of stroke work to the “double product” of heart rate
times systolic blood pressure. MEEi was calculated as MEE/LV mass, and analyzed in quartiles.
During a follow-up study of 9.2 ± 2.3 years, 126 participants developed HF (7%). HF was preceded
by acute myocardial infarction (AMI) in 94 participants. A Kaplan-Meier plot, in quartiles of
MEEi, demonstrated significant differences, substantially due to the deviation of the lowest quartile
(p < 0.0001). Using AMI as a competing risk event, sequential models of Cox regression for incident
HF (including significant confounders), demonstrated that low MEEi predicted incident HF not
due to AMI (p = 0.026), after adjustment for significant effect of age, LVH, prolonged LV relaxation,
diabetes, and smoking habits with negligible effects for sex, hypertension, antihypertensive therapy,
obesity, and hyperlipemia. Low LV mechano-energetic efficiency per unit of LVM, is a predictor of
incident, non-AMI related, HF in subjects with initially normal EF.
Keywords: left ventricular hypertrophy; heart failure with preserved ejection fraction; population
study; stroke volume; heart rate; echocardiography
1. Introduction
Heart failure (HF) is predominantly a disease of the elderly, with nearly 50% of patients having
preserved (p) left ventricular (LV) ejection fraction (EF) [1]. Although mechanisms for HFpEF remain
incompletely understood, diastolic dysfunction, because it underlies myocardial hypertrophy and
fibrosis, is thought to play a dominant role [2]. However, diastolic dysfunction also occurs in systolic HF
(HFrEF) and is also common in elderly hypertensive individuals without HF [3]. Thus, abnormalities
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other than diastolic function are likely to be involved in HFpEF, especially in the presence of LV
hypertrophy (LVH) [4].
There is evidence that pressure-overload LVH preserves EF as a measure of LV systolic function at
the chamber level, even when contractility is reduced at the level of cardiomyocytes [5]. However,
when paralleling the magnitude of LV chamber dimensions, even at normal values of LV systolic
chamber function, important differences can occur in the magnitude of stroke volume (SV, i.e. LV
pump performance), heart rate (HR), and blood pressure (BP) [6]. As a consequence, at a given EF,
hemodynamic workload might differ substantially [6] and, in fact, SV is more predictive of incident
HF than EF [7].
A new parameter of LV performance has been recently proposed as a surrogate measure of
myocardial mechano-energetic efficiency (MEE), which is the ratio between produced external systolic
work (stroke work, SW) and an estimate of myocardial oxygen consumption (MVO2) [8]. MEE per unit
of LV mass (MEEi) has been demonstrated to predict composite adverse cardiovascular (CV) events in
treated hypertensive patients after adjustment for LVH [9].
One unexplored issue is whether MEEi can also help explain incidence of HF, after adjustment for
LVH, in the presence of initial normal EF in population studies. Accordingly, this analysis has been
designed to assess whether MEEi can improve the identification of phenotypes at high risk of incident
HF in members of the “Strong Heart Study” (SHS) cohort who were free of prevalent cardiovascular
(CV) disease and initially had normal EF.
2. Methods
2.1. Participants
We analyzed data from the SHS, a population-based cohort study of CV risk factors and disease
in American Indians. Detailed descriptions of the study design and methods have been previously
reported [10]. At time of enrollment, a total of 4549 American Indian men and women, aged 45
to 74 years, from communities in Arizona, southwestern Oklahoma, and South and North Dakota
participated in the first SHS examination, conducted from 1989 to 1991 (phase 1). The cohort was
followed and re-examined twice and has been under continuous yearly surveillance for CV events.
The second examination evaluated 89% of all surviving members of the original cohort, who also
underwent standard Doppler echocardiography. Thus, the second SHS examination was used as
baseline for the present analysis.
From the population of 2794 participants available for the analysis, we excluded 441 participants
with prevalent CV (220 with a history of myocardial infarction or cardiac ischemic disease, 44 with a
history of stroke and 177 with chronic heart failure) and 94 for low ejection fraction (i.e <50%), 14 because
of serum triglycerides (>750 mg/dL), and 333 participants because of incomplete echocardiographic
assessment. Thus, for the present study, we included 1912 SHS participants (age 59 ± 8 years; 64%
women) with baseline preserved EF and without prevalent CV disease. Institutional review boards
of the participating institutions and the participating tribes approved the study and submission of
the manuscript.
2.2. Measurements and Definitions
The SHS used standard methodology and strict quality control at each clinical examination [11],
which included a personal interview, physical examination with anthropometric and blood pressure
measurement, and morning blood sample collection after a 12-hour fast. Exams were performed at
local community settings and Indian Health Service clinics by trained study staff.
Arterial hypertension was defined as blood pressure ≥140/90 mmHg or current antihypertensive
treatment. Obesity was classified as body mass index ≥30 kg/m2. Diabetes was defined as fasting
glucose ≥126 mg/dL or use of antidiabetic medication. Hyperlipemia was defined as total cholesterol
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>200 mg/dL and/or triglyceridemic value >150 mg/dL. Smoking habits were defined as non-smoker,
former smoker, and current smoker.
2.3. Echocardiography
Echocardiograms were performed using phased-array machines, with M-mode, two-dimensional,
and Doppler capabilities, as previously reported [12]. Echocardiograms were evaluated in the Core
Laboratory at the Weill Cornell Medical College in New York by expert readers blinded to the
participant’s clinical details, using a computerized review station (Digisonics, Inc., Houston, TX, USA)
equipped with digitizing tablets and monitor screen overlays for calibration and performance of each
needed measurement. Reproducibility of echocardiographic measures was tested in the Weill Cornell
adult echocardiography laboratory in an ad hoc designed study [13].
LV internal dimensions and wall thickness were measured as end-diastole and end-systole,
respectively, as previously reported [12]. Relative wall thickness, LV mass, and LV mass index (by
normalization for height in m2.7) were also estimated [6]. LVH was defined with LV mass index
>47 g/m2.7 for both sexes, a validated population-specific cut-point, maximizing the population risk
attributable to LVH [14]. SV was calculated as the difference between LV end-diastolic and end-systolic
volumes by the z-derived method [6,15]. EF was obtained by the ratio of SV to end-diastolic volume.
Midwall fractional shortening was measured as previously described [16].
The ratio of early to late peak diastolic velocities (E/A ratio) was measured as previously
described [17]. Based on previous analyses in the SHS, the E/A ratio was categorized as “normal” when
it was between 0.6 and 1.5, in “prolonged relaxation” when it was <0.6 and in “restrictive physiology”
when it was >1.5 [17].
To assess MEE, we estimated SW as the product of systolic BP times SV (mmHg ×mL). Myocardial
oxygen consumption (MVO2) could be estimated using the “double product” (DP) of systolic BP ×
heart rate [18]. Using this second method, MEE may be estimated in mL/s:
MEE =
SW
DP
≈ mmHg×mL
mmHg× bpm =
mL
bpm× 60−1 =
mL
s
(1)
Because of the reportedly close dependence of MEE on LV mass, normalization for LV mass was
done to estimate energetic expenditure per unit of myocardial mass (MEEi in mL/s/g) [9].
2.4. Outcome
CV events were recorded and adjudicated as previously reported using standardized criteria. [10].
The end-point of the present study was the first occurrence of HF, defined by the Framingham criteria
for HF, as previously described [7]. Due to the potential interference with the analyzed outcome,
occurrence of acute myocardial infarction (AMI) prior to HF was also censored for analysis as a
competing risk event.
2.5. Statistical Analysis
Data were analyzed using IBM-SPSS-statistics (version 23.0; SPSS, New Jersey), and expressed as
mean ± 1SD. MEEi was categorized in quartiles and analyzed in exploratory analyses, using linear
contrast for trend analysis for age and Kendall’s tau as a test for monotonic trends with categorical
variables. Cumulative incidences of HF in quartiles of MEEi were analyzed using a Kaplan-Meier
plot. Further analyses were focused on the lowest MEEi (corresponding to 25th percentile of the
distribution).
We calculated hazard ratios and 95% confidence intervals (CI) of incident HF, using three sequential
models of Cox regression. In the first Cox model, the outcome was analyzed in relation to LVH and
patterns of E/A ratio, adjusting for age and sex. In the second model, low MEEi, hypertension and
anti-hypertensive therapy (no/yes) were forced into the model. In the third model, obesity and diabetes
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were added to explore how the previous models could be changed by the co-presence of additional CV
risk factors. Since the end-point of the present analysis, HF, can also be a consequence of a preceding
AMI, a Cox regression was run using AMI preceding HF as a competing risk event. Thus, we censored
AMI occurring before HF, in competition with the primary predictor, MEEi [19].
3. Results
Among 1912 SHS participants with normal EF and without prevalent CV disease included in this
analysis, prevalence of arterial hypertension, obesity, and diabetes were 27, 51, and 40%, respectively.
Table 1 shows that while age was similar among quartiles of MEEi, the proportion of women
was progressively lower with decreasing quartiles of MEEi, and concentric LV geometry and LVH
were progressively higher (all p for trend <0.0001), paralleling the progressive increase in prevalent
hypertension, obesity, and diabetes (all p for trend <0.0001). There was a significant trend for mitral
E/A ratios of <0.6 to sharply increase in the lowest quartile of MEEi, whereas mitral E/A ratios of >1.5
progressively decreased with decreasing quartiles of MEEi (all p for trend <0.0001). Hyperlipemia and
smoking habits were not different within quartiles of MEEi.
Table 1. Characteristics of quartiles of LV mass-normalized myocardial mechano-energetic
efficiency (MEEi).
Quartiles of Indexed
Myocardial Mechano-Energetic Efficiency
Whole Population ≥0.45 0.40–0.44 0.35–0.39 ≤0.34
(n = 1912) (n = 478) (n = 477) (n = 479) (n = 478)
Age (years) 59 ± 8 59 ± 8 60 ± 8 59 ± 8 60 ± 8
Hypertension (%) a 27% 22% 25% 29% 34%
Proportion of women (%) a 64% 68% 69% 65% 55%
Concentric LV geometry (%) a 4% 0.2 % 1% 2% 11%
LV Hypertrophy (%) a 23% 9% 18% 23% 40%
Mitral E/A ratio <0.6 (%) a 4.1 2.1 2.5 1.3 10.5
Mitral E/A ratio >1.5 (%) a 2.6 4.5 3.4 1.5 1.1
Obesity (%) a 51% 40% 51% 57% 58%
Diabetes (%) a 40% 25% 37% 41% 57%
Hyperlipemia (%) 58 57 55 59 62
Former smoker (%) 35 33 34 36 38
Current smoker 36 39 35 34 35
LV = left ventricular; a Kendall’s τ-b: all p < 0.0001.
Although only patients with initially normal EF were included in this study, 12% of variability of
EF was explained by MEEi, but the explained variability rises to 42% when LV systolic function was
evaluated by midwall shortening.
During follow-up studies (median 9.9 years, inter-quartile range 9.3–10.4 years), 126 (7%)
participants developed HF, 94 of them after AMI. A Kaplan-Meier cumulative hazard plot demonstrated
a significant log-rank, substantially due to the marked deviation of the lowest quartiles of MEEi
(Figure 1).
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Figure 1. Cumulative hazard of incident heart failure (HF) for quartiles of myocardial mechano-
energetic efficiency per unit of left ventricular mass (MEEi). Continuous grey line represents the 
lowest MEEi quartile. 
As seen in Figure 1, we compared the lowest MEEi quartile (i.e. ≤0.34 ml × s-1 × g-1) with all others, 
defined for convenience as "normal MEEi". Low MEEi was present in 47% of the subgroup, compared 
to 24% in the subgroup without incident HF (p < 0.0001). Table 2 shows sequential models of Cox 
regressions for incident HF. Low MEEi predicted incident HF after adjustment for LVH and 
prolonged relaxation. The impact of low MEEi was reduced after the inclusion of diabetes and 
smoking habits into the model. 
The Cox models were also run using continuous variables for systolic blood pressure, body mass 
index, MEEi, and LV mass index instead of categories, without modifications, and compared to what 
has been reported in Table 2. Specifically, for each unit of increasing MEEi, there was a significant 2% 
reduction of hazard of incident-adverse CV events (hazard ratio (HR)= 0.02; 95% CI 0.002–0.347; p < 
0.006). 
Figure 1. Cumulative hazard of incident heart failure (HF) for quartiles of myocardial mechano-energetic
efficiency per unit of left ventricular mass (MEEi). Continuous grey line represents the lowest
MEEi quartile.
As se n in Figure 1, l st EEi quartile (i.e. ≤0.34 mL × s−1 × g−1) with all
others, efined for co v nie ce as “normal MEEi”. Lo MEEi was present in 47% of the subgroup,
compared to 24% in the subgroup without incident HF (p < 0.0001). Table 2 hows sequential models
of Cox regressions for i cident HF. Low MEEi predicted incident HF after adjustment V and
prolonged relax tion. The impact of low MEEi was reduced after the inclusion of diabetes and smoking
habits to the model.
The Cox models were also run using continuous variables for systolic blo d pres ure, body mas
index, ME i, and LV mas index instead of categories, without modifications, and compared to what
has be n reported i a le . ecifica ly, for each unit of increasing M Ei, th re was a significant
2% reduction of h zard of incident-adverse CV vents (h zard ratio (HR)= 0.02; 95% CI .002–0.347;
p < .006).
A multicollinearity test was performed using all covariates of model 3 to calculate the variance
inflation factor (VIF). The value of VIF was always <1.9, demonstrating optimal performance of the
model and the low level of multicollinearity between LVH and low MEEi.
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Table 2. Sequential models of proportional hazard analysis of incident heart failure (HF) in relation to low MEEi.
Predictors Model 1 Model 2 Model 3
p HR 95%CI p HR 95%CI p HR 95%CI
Age (years) 0.004 1.04 1.01–1.06 0.007 1.04 1.01–1.06 0.001 1.05 1.02–1.08
Female sex 0.666 0.93 0.62–1.38 0.846 0.96 0.63–1.46 0.833 1.05 0.68–1.61
LV Hypertrophy <0.0001 2.51 1.70–3.73 0.001 2.01 1.37–3.10 0.004 1.89 1.23–2.91
E/A <0.6 <0.0001 3.72 1.99–6.98 0.002 2.85 1.48–5.51 0.004 2.60 1.35–5.05
E/A >1.5 0.612 0.60 0.08–4.33 0.629 0.61 0.09–4.43 0.800 0.77 0.11–5.60
Low MEEi 0.005 1.83 1.21–2.79 0.026 1.61 1.06–2.44
Hypertension 0.484 1.27 0.66–2.45 0.672 1.15 0.60–2.23
Anti-hypertensive therapy (y/n) 0.012 2.28 1.20–4.35 0.094 1.75 0.91–3.35
Diabetes <0.0001 3.11 2.01–4.80
Obesity 0.191 0.76 0.50–1.15
Hyperlipemia 0.832 0.96 0.64–1.43
Former smoker 0.006 2.11 1.24–3.60
Current Smoker 0.003 2.38 1.35–4.17
LV = left ventricular; MEEi = indexed myocardial mechano-energetic efficiency; HR = hazard ratio.
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4. Discussion
Our analysis demonstrates that in a population-based study with initially normal left ventricular
ejection fraction (LVEF), reduced myocardial mechano-energetic efficiency for each g of myocardial
mass is a strong predictor of incident HF after adjustment for LVH, prolonged relaxation, and associated
CV risk factors, including hypertension, obesity, diabetes, and smoking habits. Our analysis merged
CV risk factors with markers of preclinical CV disease. The causative effect of primary risk factors was
largely offset by their direct effects on the CV system. The only risk factor that could not be fully offset
by CV phenotype was diabetes, which in fact remains a potent risk factor for HF, even after adjustment
for CV phenotype, as we have previously demonstrated [20].
In our analysis, we provided an estimation of myocardial energetic efficiency using a very
simple method on the basis of a simple assumption, which has been already used in different
circumstances [5,18], i.e., that MVO2 consumption mainly depends on developed pressure and
frequency of contraction. More complex models of estimating myocardial oxygen consumption have
been proposed, with strong rationale, but are likely less suitable for a clinical use [21].
4.1. The Conundrum of Development of HF
It is not surprising that a condition of low myocardial mechano-energetic efficiency per unit of
myocardial mass significantly contributes to identifying a CV phenotype at risk of developing HF. The
link between alterations of myocardial energy balance and HF should merit more attention, especially
in the setting of HFpEF. Although we do not have follow-up echocardiograms to compare, we may
postulate that incident HFpEF is frequent in our population sample, because our hazard analysis
was controlled for incident, intercurrent AMI as a competing risk factor for incident HF, indirectly
minimizing the chance that post-ischemic systolic HF could play a substantial role in our findings.
Given the frustrating results related to the attempt to improve outcomes in HFpEF [22] and related
to the insufficient understanding of its mechanisms, shifting the attention from hemodynamics and
cardiac mechanics to the process of production and utilization of energy might be productive [23].
Although increased LV mass is in fact a critical marker of risk, considerable heterogeneity can be
found, especially in the setting of HFpEF. In clinical trials and contemporary registries, approximately
one-third to two-thirds of patients with HFpEF do not exhibit clear-cut LVH [24]. A proportion of
HFpEF patients exhibit eccentric LVH rather than the more usual concentric pattern [24]. Even more
intriguing is the evidence that approximately 50% of patients with HFpEF and normal LV mass do not
have hypertension [24].
Furthermore, it is noteworthy that in this population with normal EF at baseline, MEEi could
explain as much as 42% of midwall shortening variability, compared to the expected negligible
correlation with ejection fraction. This finding is physiologically consistent with the assumption that
LV systolic chamber function is only a very rough indicator of the status of myocardial mechanics.
Other pathogenetic mechanisms should be investigated.
4.2. Diastolic Dysfunction
Diastolic dysfunction is considered especially important in the context of HFpEF [24]. However,
in echocardiographic sub-studies, one-third of patients randomized in controlled trials of HFpEF
exhibited normal diastolic function, and a further 20% to 30% only had mild or grade 1 diastolic
dysfunction [24]. In addition, a recent study of elderly subjects (age 67 to 90 years) without HF found
that 96% of them had abnormal diastolic function, according to guideline-based definitions. In a
condition in which diastolic dysfunction has been considered a definite pathophysiologic feature
(“diastolic heart failure”), it is unclear whether the absence of diastolic dysfunction in HFpEF reflects
a limitation of echocardiography, at least at the light of the present recommendations, or suggests
pathophysiological mechanisms that are independent of diastolic function in a substantial proportion
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of patients. But, perhaps even more importantly, HF is always characterized by increased filling
pressure (and therefore real diastolic dysfunction), no matter whether or not EF is reduced.
4.3. LV Production, Delivery, and Utilization of Energy
The evidence of impaired myocardial energy balance adds pathophysiological rationale to the
strong effect of increased LV mass function as a marker of risk for HF. The index presented in this and
in previous longitudinal analyses [9] allows a concentration of attention on physiological mechanisms
more related to the production, delivery, and utilization of energy. While normal hearts mainly oxidize
fatty acids to produce energy (ATP), hearts with stage B HF require a shift of production of energy
(ATP) toward the most convenient glucose-pyruvate oxidation, a shift that implies adequate insulin
sensitivity [25].
An important possible mechanism reducing myocardial efficiency is in fact insulin resistance [26].
The emerging evidence that this index is influenced by conditions of insulin resistance [25] is an
indirect validation of our physiologic postulate. This is evident in the present and previous analyses in
which diabetes exhibits a substantial importance as a predictor of HF, even more than hypertension
(confirmed in the present analysis, as seen in Table 2). The progressive decline of MEEi with the
increasing prevalence of diabetes and obesity was demonstrated previously in our Italian registry
of hypertensive patients [9,25]. Insulin resistance, typical of type 2 diabetes, results in difficulty in
the utilization of glucose [27], increasing reliance on fatty acid oxidation for up to 80–90% of acetyl
CoA, at the expense of glucose and lactate oxidation [28]. This increase in fatty acid oxidation is the
main determinant of the increased MVO2 at zero work, because of the lower oxygen efficiency for ATP
synthesis using fatty acids as substrates [29].
Due to the above considerations and given the ethnic specificity of the SHS, and the particular
high prevalence of diabetes and obesity, our findings are not necessarily generalizable and might need
to be clarified in other populations with different genetic and environmental backgrounds, especially
because algorithms for risk prediction might be substantially affected by prevalence and distribution
of individual risk factors [30].
4.4. Final Considerations
Despite the strong association with incident HF, many unconsidered factors could have an
impact on the progression of HF, potentially reducing the impact of baseline low myocardial
mechano-energetic efficiency during follow-up. Among them, the control of diabetes or blood
pressure during follow-up could have a significant impact on the progression of diastolic dysfunction
and precipitation of HF. Further studies should help clarifying pathophysiological mechanisms
linking myocardial mechano-energetic efficiency to diastolic dysfunction and control of blood pressure
and diabetes.
5. Conclusions
This study demonstrated that depressed LV mechano-energetic efficiency per unit of LV mass,
computed by using a simple approach comparing external work with the estimated oxygen consumption,
is a powerful predictor of incident HF after adjustment for LVH and other confounders in an unselected
population-based cohort of American Indians with normal baseline EF. Our results might serve as a
hypothesis when testing for a better evaluation of pathophysiology of HFpEF.
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